泰林生物 reported revenue of ¥0.17B for the period ended 2026-06-30, +13.4% year on year. Net income was ¥0.02B, a 12.3% net margin on a 49.0% gross margin. The largest revenue line is 微生物检测技术系列产品 at 42% of the total. Free cash flow for the period was ¥0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.17B | +13.4% |
| Gross profit | ¥0.08B | — |
| Operating income | ¥0.02B | — |
| Net income | ¥0.02B | +52.7% |
| Gross margin | 49.0% | Net margin 12.3% |
| Revenue Q/Q | +36.0% | — |
| Segment | Revenue | Share |
|---|---|---|
| 微生物检测技术系列产品 | ¥0.07B | 42.2% |
| 无菌生产与污染控制设备系列产品 | ¥0.06B | 37.9% |
| 有机物分析技术系列产品 | ¥0.02B | 10.2% |
| 其他 | ¥0.01B | 8.2% |
| 其他主营业务 | ¥0.00B | 1.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.08B | 51.0% |
| R&D | ¥0.03B | 15.5% |
| SG&A | ¥0.04B | 23.4% |
| Tax & other | ¥0.00B | 0.9% |
| Item | Amount |
|---|---|
| Total assets | ¥0.94B |
| Total liabilities | ¥0.15B |
| Shareholders' equity | ¥0.79B |
| Equity / assets | 84.3% |
| Operating cash flow | ¥0.02B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥0.01B |
| Cash conversion (OCF / net income) | 104% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
中富电路 ・ 玉禾田 ・ 艾可蓝 ・ 双飞集团 ・ 耐普矿机 ・ 聚杰微纤 ・ 英杰电气 ・ 东岳硅材 ・ 贝仕达克 ・ 建科智能 ・ 北鼎股份 ・ 阿尔特
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies